SITE Centers logo

SITE CentersNYSE: SITC

Profile

Industry:

Retail

Country:

United States

IPO:

02 February 1993

Next earnings report:

N/A

Last dividends:

18 June 2024

Next dividends:

N/A
$842.03 M
-73%vs. 3y high
40%vs. sector
-94%vs. 3y high
0%vs. sector
-77%vs. 3y high
11%vs. sector
-73%vs. 3y high
28%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:16:11 GMT
$16.06+$0.11(+0.69%)
$90.76 M$85.78 M
$90.76 M$322.95 M

Analysts recommendations

Institutional Ownership

SITC Latest News

Compared to Estimates, SITE Centers Corp. (SITC) Q3 Earnings: A Look at Key Metrics
zacks.com30 October 2024 Sentiment: POSITIVE

While the top- and bottom-line numbers for SITE Centers Corp. (SITC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
globenewswire.com30 October 2024 Sentiment: POSITIVE

Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
globenewswire.com30 October 2024 Sentiment: POSITIVE

WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024.

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
prnewswire.com30 October 2024 Sentiment: POSITIVE

-  Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody, at SITC 2024.

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
prnewswire.com28 October 2024 Sentiment: POSITIVE

SAN JOSE, Calif. , Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held virtually and in Houston, Texas, from November 6-10, 2024.

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
accesswire.com22 October 2024 Sentiment: POSITIVE

FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually. Details of the presentation are as follows: Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC Abstract Number: 765 Presenter: Reid Bissonnette, Ph.D.

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
globenewswire.com16 October 2024 Sentiment: POSITIVE

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
globenewswire.com09 October 2024 Sentiment: POSITIVE

SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024.

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
globenewswire.com07 October 2024 Sentiment: POSITIVE

WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced three upcoming poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 6-10, 2024 in Houston.

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
globenewswire.com04 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.

What type of business is SITE Centers?

SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.

What sector is SITE Centers in?

SITE Centers is in the Real Estate sector

What industry is SITE Centers in?

SITE Centers is in the Retail industry

What country is SITE Centers from?

SITE Centers is headquartered in United States

When did SITE Centers go public?

SITE Centers initial public offering (IPO) was on 02 February 1993

What is SITE Centers website?

https://www.sitecenters.com

Is SITE Centers in the S&P 500?

No, SITE Centers is not included in the S&P 500 index

Is SITE Centers in the NASDAQ 100?

No, SITE Centers is not included in the NASDAQ 100 index

Is SITE Centers in the Dow Jones?

No, SITE Centers is not included in the Dow Jones index

When was SITE Centers the previous earnings report?

No data

When does SITE Centers earnings report?

Next earnings report date is not announced yet